1. S149: LONG TERM OUTCOMES OF IFCG REGIMEN FOR FIRSTLINE TREATMENT OF PATIENTS WITH CLL WITH MUTATED IGHV AND WITHOUT DEL(17P)/TP53 MUTATION. (23rd June 2022) Authors: Jain, N.; Thompson, P.; Burger, J.; Ferrajoli, A.; Takahashi, K.; Estrov, Z.; Borthakur, G.; Bose, P.; Kadia, T.; Pemmaraju, N.; Sasaki, K.; Konopleva, M.; Jabbour, E.; Garg, N.; Wang, X.; Kanagal-Shamanna, R.; Patel, K.; Wang, W.; Wang, S.; Jorgensen, J. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 50 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗